Scientech Research LLC Purchases 2,386 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Scientech Research LLC raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 193.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,622 shares of the biopharmaceutical company's stock after buying an additional 2,386 shares during the period. Regeneron Pharmaceuticals comprises about 0.7% of Scientech Research LLC's holdings, making the stock its 4th largest position. Scientech Research LLC's holdings in Regeneron Pharmaceuticals were worth $2,580,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Pamalican Asset Management Ltd acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $4,915,000. Intact Investment Management Inc. acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $356,000. Rhenman & Partners Asset Management AB raised its stake in Regeneron Pharmaceuticals by 11.4% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock valued at $30,956,000 after buying an additional 4,457 shares in the last quarter. Fagan Associates Inc. raised its stake in Regeneron Pharmaceuticals by 42.2% in the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock valued at $9,205,000 after buying an additional 3,832 shares in the last quarter. Finally, Golden State Equity Partners raised its stake in Regeneron Pharmaceuticals by 1,479.1% in the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock valued at $967,000 after buying an additional 1,272 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

REGN has been the subject of a number of research analyst reports. Truist Financial decreased their target price on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Canaccord Genuity Group raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 22nd. StockNews.com cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. Citigroup raised Regeneron Pharmaceuticals from a "neutral" rating to a "buy" rating and upped their target price for the company from $600.00 to $700.00 in a research report on Wednesday, May 14th. Finally, Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 target price for the company. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $890.60.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded up $18.25 on Tuesday, hitting $614.79. 1,102,019 shares of the company's stock were exchanged, compared to its average volume of 792,581. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm's 50-day moving average price is $598.10 and its two-hundred day moving average price is $680.17. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $520.50 and a fifty-two week high of $1,211.20. The firm has a market cap of $66.38 billion, a price-to-earnings ratio of 16.06, a P/E/G ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business's revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $9.55 EPS. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.57%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.